Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.

MLA

Joensuu, Heikki, et al. “Adjuvant Capecitabine in Combination with Docetaxel and Cyclophosphamide plus Epirubicin for Breast Cancer: An Open-Label, Randomised Controlled Trial.” The Lancet. Oncology, vol. 10, no. 12, Dec. 2009, pp. 1145–51. EBSCOhost, https://doi.org/10.1016/S1470-2045(09)70307-9.

APA

Joensuu, H., Kellokumpu-Lehtinen, P.-L., Huovinen, R., Jukkola-Vuorinen, A., Tanner, M., Asola, R., Kokko, R., Ahlgren, J., Auvinen, P., Hemminki, A., Paija, O., Helle, L., Nuortio, L., Villman, K., Nilsson, G., Lahtela, S.-L., Lehtiö, K., Pajunen, M., Poikonen, P., … Lindman, H. (2009). Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. The Lancet. Oncology, 10(12), 1145–1151. https://doi.org/10.1016/S1470-2045(09)70307-9

Chicago

Joensuu, Heikki, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Arja Jukkola-Vuorinen, Minna Tanner, Raija Asola, Riitta Kokko, et al. 2009. “Adjuvant Capecitabine in Combination with Docetaxel and Cyclophosphamide plus Epirubicin for Breast Cancer: An Open-Label, Randomised Controlled Trial.” The Lancet. Oncology 10 (12): 1145–51. doi:10.1016/S1470-2045(09)70307-9.